Biohaven Ltd. (NYSE:BHVN) Shares Bought by Transatlantique Private Wealth LLC

Transatlantique Private Wealth LLC lifted its position in shares of Biohaven Ltd. (NYSE:BHVN) by 52.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,707 shares of the company’s stock after purchasing an additional 2,657 shares during the period. Transatlantique Private Wealth LLC’s holdings in Biohaven were worth $268,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Redwood Wealth Management Group LLC purchased a new stake in Biohaven during the 2nd quarter valued at approximately $61,000. Elkhorn Partners Limited Partnership purchased a new stake in shares of Biohaven in the second quarter valued at about $125,000. Prevail Innovative Wealth Advisors LLC acquired a new position in shares of Biohaven during the fourth quarter worth about $230,000. Private Advisor Group LLC purchased a new position in Biohaven during the fourth quarter worth about $231,000. Finally, Capstone Investment Advisors LLC acquired a new stake in Biohaven in the fourth quarter valued at about $235,000. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on BHVN. Sanford C. Bernstein started coverage on Biohaven in a research report on Wednesday, September 4th. They set an “outperform” rating and a $55.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $59.00 price target on shares of Biohaven in a report on Thursday, May 30th. Cantor Fitzgerald restated an “overweight” rating on shares of Biohaven in a research report on Monday, August 19th. Morgan Stanley initiated coverage on Biohaven in a research note on Wednesday, July 24th. They set an “overweight” rating and a $58.00 price target on the stock. Finally, Jefferies Financial Group initiated coverage on Biohaven in a report on Monday, September 16th. They set a “buy” rating and a $57.00 price objective for the company. Eleven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $54.70.

Biohaven Stock Down 0.1 %

Shares of NYSE:BHVN opened at $40.39 on Friday. The company has a market capitalization of $3.57 billion, a P/E ratio of -5.91 and a beta of 1.30. The stock’s fifty day simple moving average is $38.35 and its 200-day simple moving average is $41.07. Biohaven Ltd. has a 52-week low of $16.45 and a 52-week high of $62.21.

Biohaven (NYSE:BHVN) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($3.64) EPS for the quarter, missing analysts’ consensus estimates of ($1.72) by ($1.92). On average, sell-side analysts anticipate that Biohaven Ltd. will post -8.92 earnings per share for the current year.

Insider Activity

In other Biohaven news, Director John W. Childs purchased 28,400 shares of the stock in a transaction on Thursday, July 18th. The stock was bought at an average price of $35.67 per share, for a total transaction of $1,013,028.00. Following the acquisition, the director now directly owns 2,339,741 shares of the company’s stock, valued at $83,458,561.47. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 16.00% of the company’s stock.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.